drugset / Trial / NCT04336501

Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

NCT04336501

NaSingle-groupOpen-labelTreatment

Summary

Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation

Timeline

Start
2019-01-01
Primary completion
2021-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IM19 Cell therapy
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule

Indications